Last updated: February 13, 2026
Overview
The drug with NDC 60687-0272 is identified as Zeposia (ozanimod), developed by Celgene, now part of Bristol-Myers Squibb. Zeposia is an orally administered sphingosine 1-phosphate receptor modulator indicated for multiple sclerosis (MS) and ulcerative colitis (UC). The drug secured FDA approval for relapsing forms of MS in March 2020 and for UC in May 2023.
Market Landscape
Indications and Market Penetration
-
Multiple Sclerosis (MS): Zeposia competes with drugs such as Novartis's Gilenya (fingolimod), Biogen's Tecfidera (dimethyl fumarate), and emerging oral therapies like BMS's Junctura (siponimod).
-
Ulcerative Colitis (UC): Competes with infliximab, adalimumab, vedolizumab, and Janus kinase inhibitors. Zeposia is positioned as an oral alternative with a potentially improved safety profile.
Market Size
-
MS: The global MS drug market was valued at approximately $22 billion in 2022, with a compound annual growth rate (CAGR) of 3-5%. The U.S. leads, accounting for 60% of sales.
-
UC: The UC market in North America reached about $5 billion in 2022, with expected annual growth of approximately 4%.
Market Share and Adoption
-
Since launch, Zeposia has gained a modest share in MS, with initial prescriber adoption primarily among patients transitioning from injectable therapies.
-
For UC, uptake is emerging, contingent on comparative efficacy and safety data.
-
Key factors influencing market share include its oral route, safety profile, and competitive positioning against established biologics.
Pricing Strategy and Cost Analysis
Current List Prices
-
MS: Approximate monthly wholesale acquisition cost (WAC) is $7,000, translating to an annual cost of roughly $84,000.
-
UC: Estimated at similar WAC levels, accounting for dosing adjustments.
Price Comparisons
| Drug Name |
Indication |
Monthly WAC |
Annual Cost |
Administration Type |
| Zeposia (ozanimod) |
MS & UC |
~$7,000 |
~$84,000 |
Oral |
| Gilenya (fingolimod) |
MS |
~$8,000 |
~$96,000 |
Oral |
| Tecfidera (dimethyl fumarate) |
MS |
~$7,500 |
~$90,000 |
Oral |
| Humira (adalimumab) |
UC & other |
~$4,800 |
~$58,000 |
Subcutaneous |
Reimbursement and Cost-Effectiveness
Reimbursement rates vary based on insurance and formulary positioning. Payers favor oral agents that demonstrate comparable efficacy at lower or similar costs, driving potential discounts or pricing strategies.
Pricing Projections
-
Short-term (1-2 years): Maintain list price with modest discounts (~10-15%) to accelerate market penetration.
-
Medium-term (3-5 years): Price may stabilize or slightly decrease as generic or biosimilar competition emerges, especially in UC.
-
Long-term (5+ years): Potential reduction in pricing as patent exclusivity wanes; increased market competition could lead to a 20-30% price decrease from peak levels.
Sales Forecast and Revenue Potential
Assumptions
Estimated Revenue (2023-2027)
| Year |
Estimated MS Sales |
Estimated UC Sales |
Total Revenue |
| 2023 |
$150 million |
$50 million |
$200 million |
| 2024 |
$300 million |
$100 million |
$400 million |
| 2025 |
$500 million |
$200 million |
$700 million |
| 2026 |
$700 million |
$300 million |
$1 billion |
| 2027 |
$1 billion |
$400 million |
$1.4 billion |
Note: These figures account for gradual adoption, competitive pressures, and payer negotiations.
Key Factors Affecting Price and Market
-
Patent Life and Exclusivity: Patent protection extends until approximately 2030; biosimilar or generic competition is unlikely during this period.
-
Regulatory Approvals: Additional indications or label expansions can elevate pricing power.
-
Market Competition: Emergence of new therapies, especially oral or convenience-focused agents, may pressure prices.
-
Patient Access Programs: Rebates and patient assistance programs can influence net pricing and reimbursement.
Conclusion
Zeposia possesses a competitive moderate market position driven by oral administration, with current list prices around $7,000/month. Market share growth depends on effective differentiation and payer acceptance. Pricing strategies are expected to remain relatively stable over the near term, with potential reductions over the longer term due to competitive dynamics.
Key Takeaways
- Zeposia's annual revenue in the U.S. could reach up to $1.4 billion by 2027 under optimistic market share assumptions.
- List prices are comparable to other oral MS therapies but remain above biologics. Discounting will likely influence net pricing.
- Market penetration depends on prescriber acceptance, insurance coverage, and competitive threats, especially in UC.
- Patent exclusivity supports premium pricing through 2030, but biosimilar and generic pressures could emerge thereafter.
- Strategic pricing, access programs, and clinical differentiation are critical to maximizing revenue.
FAQs
1. How does Zeposia compare in efficacy to other MS treatments?
Zeposia has demonstrated comparable efficacy to other oral MS agents in clinical trials, with a favorable safety profile, making it a competitive alternative.
2. What are the primary drivers of Zeposia’s market adoption?
Patient preference for oral therapy, prescriber familiarity, reimbursement policies, and safety profile enhancements drive adoption.
3. Is Zeposia likely to face generic competition soon?
No, patent protection extends until approximately 2030, preventing generic or biosimilar competition within the foreseeable future.
4. How will pricing change with increasing market share?
Pricing is expected to remain stable short-term, with potential discounts and rebates increasing as competition rises or patent exclusivity diminishes.
5. What factors could influence future price projections?
Regulatory changes, emerging therapies, reimbursement policies, patent extensions, or patent challenges could significantly alter pricing strategies.
References
- [1] IQVIA. "Global MS Market Analytics," 2022.
- [2] Bristol-Myers Squibb. "Zeposia (ozanimod) FDA Approval Announcement," 2020.
- [3] MarketWatch. "Ulcerative Colitis Drugs Market Size & Growth Analysis," 2022.
- [4] EvaluatePharma. "MS Market Outlook," 2022.
- [5] FDA. "Zeposia (ozanimod) Label and Regulatory Documents," 2023.
